We operate through two business areas: Haemophilia and Specialty Care. The research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases.
In Haemophilia, we aim to achieve a leadership position in Europe, the Middle East and Africa.
In Specialty Care, we provide products for the treatment of inflammatory and genetic diseases as well as a number of specialist indications. We plan to expand our portfolio to get the most out of our competence and capacity in rare disease and niche indications.